Immunodeficiencies Presenting with Inflammatory Bowel Disease

This course if part of the 2017 Virtual Annual Meeting.  Want more virtual meeting recordings?  Save by ordering the full set!

Session 4812 from the 2017 AAAAI Annual Meeting discusses immunologic mechanisms underlying very early onset inflammatory bowel disease and identifies current therapies and outcomes for early onset.

Target Audience

Physicians
Allergists/Immunologists
Nurses
Nurse Practitioners
Allied Health Professionals

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Recognize underlying primary immunodeficiency disease in patients with inflammatory bowel disease
  • Discuss immunologic mechanisms underlying very early onset inflammatory bowel disease
  • dentify current therapies and outcomes for early onset inflammatory bowel disease
Summary
Available credit: 
  • 1.25 Attendance
    Attendance credit.
  • 1.25 CE
    CE credit.
  • 1.25 CME
    CME credit.
Course opens: 
05/31/2017
Course expires: 
06/14/2019
Cost:
$25.00
Part of: 
Immunodeficiency - 2017 Virtual Annual Meeting Recordings
Rating: 
0

Faculty
Dr. Judith Kelsen, MD
Children's Hospital of Philadelphia, Philadelphia, PA, Kaan Boztug, MD
Relevant relationships: None

Dr. Kathleen E. Sullivan, MD PhD FAAAAI
Children's Hospital of Philadelphia, Philadelphia, PA
Relevant relationships: None

Dr. Troy R. Torgerson, MD PhD
Seattle Children's Hospital Research Institute, Seattle, WA
Relevant relationships: None

Reviewers
Anne Ditto, MD FAAAAI
Northwestern University Feinberg School of Medicine, Chicago, IL
Relevant relationships: None

Karen Gregory, DNP APRN-BC RRT AE-C
Oklahoma Allergy and Asthma Clinic, Edmond, OK
Relevant relationships: Merck, MEDA and Novartis: speakers bureau

Disclosure link: 
2017 Annual Meeting Planning, Review and Faculty Disclosures

Accreditation Statement
The American Academy of Allergy, Asthma and Immunology (AAAAI) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation Statement
The American Academy of Allergy, Asthma & Immunology designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CE Designation Statement
The American Academy of Allergy, Asthma, & Immunology (AAAAI) is a Provider, approved by the California Board of Registered Nursing, Provider #10704, for up to 1.25 Contact Hours.

Medium and Method of Physician Participation for an Enduring Activity
Follow these steps to complete the activity:

  1. Register for the activity.
  2. Review the CME and Disclosure information.
  3. Complete all required components.
  4. Complete the post-test. You must achieve a score of 70% or higher on post-tests to claim credit.
  5. Complete the activity evaluation.
  6. Claim your credits. Enter only the number of credits earned based on your participation in the activity.
  7. Print or save your certificate.

AAAAI Privacy Policy
To verify your participation in educational activities, you may be asked to provide your name, contact information, and/or other descriptors. The AAAAI will not release this information to outside entities. It may be used internally to inform you of other AAAAI educational activities. If you wish to have your information excluded from this process, please contact us at cme@aaaai.org.

Release date
Original release date: June 1, 2017.  Valid for credit through May 31, 2019.

Questions
Activity-related questions should be directed to cme@aaaai.org

Available Credit

  • 1.25 Attendance
    Attendance credit.
  • 1.25 CE
    CE credit.
  • 1.25 CME
    CME credit.

Price

Cost:
$25.00
Please login or register to take this course.

Required Hardware/software

One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari.

Internet Explorer is no longer supported.